The WACC of Generex Biotechnology Corp (GNBT) is 5.1%.
| Range | Selected | |
| Cost of equity | 136.20% - 208.20% | 172.20% |
| Tax rate | 26.20% - 27.00% | 26.60% |
| Cost of debt | 4.00% - 7.00% | 5.50% |
| WACC | 3.8% - 6.4% | 5.1% |
| Category | Low | High |
| Long-term bond rate | 4.2% | 4.7% |
| Equity market risk premium | 5.0% | 6.0% |
| Adjusted beta | 26.4 | 33.84 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 136.20% | 208.20% |
| Tax rate | 26.20% | 27.00% |
| Debt/Equity ratio | 152.88 | 152.88 |
| Cost of debt | 4.00% | 7.00% |
| After-tax WACC | 3.8% | 6.4% |
| Selected WACC | 5.1% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for GNBT:
cost_of_equity (172.20%) = risk_free_rate (4.45%) + equity_risk_premium (5.50%) * adjusted_beta (26.4) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.